Business
Commercial sales of Genedrive® HCV ID Kit begin
Commercial sales of Genedrive® HCV ID Kit begin.
About this update from Genedrive Plc
[{"type":"text","content":"\n \nRNS Number : 4897H Genedrive PLC 13 March 2018 \n\nFor release: 13 March 2018\n \ngenedrive plc (\"genedrive\" or the \"Company\")\n \nCommercial sales of Genedrive® HCV ID Kit and platform begin\n \nDecentralised molecular HCV assays shipped to Africa \n \ngenedrive plc (AIM: GDR), the near patient molecular diagnostics company, today announces that is has commenced commercial sales and shipments of its Genedrive® HCV ID Kit and Genedrive® platform into the EMEA region. The products have been shipped to genedrive's distributor, Sysmex Corporation (\"Sysmex\"), a world leader in clinical laboratory systemization and solutions, and are now destined for use in various initial target countries. In addition, first commercial sales and shipments of the Genedrive® HCV ID Kit and Genedrive® platform are expected to commence in the Asia Pacific region in the coming weeks. \nDavid Budd, Chief Executive Officer of genedrive plc, said: \"Since signing our distribution agreements with Sysmex, we have continued to build momentum in the market and we are pleased to see initial commercial sales. An ongoing process of registering the products in target countries will naturally lead to a growing opportunity, and we are confident that as the first to market decentralised qualitative molecular HCV test, Genedrive® is uniquely positioned to meet this need.\"\nWith the advent of new 'curative' direct acting antiviral treatments for Hepatitis C (HCV), genedrive and Sysmex believe that there is a major opportunity to support tackling the global burden of the disease if accurate, decentralised diagnostics can be used to identify those living with HCV and give them access to therapy. These first sales mark a further important step towards that goal.\n \nThe Genedrive® HCV ID Kit, a qualitative molecular assay for HCV has received CE-IVD Certification from the EU. Recently announced field study results demonstrated the robust performance of the HCV test in a third party setting and on samples from sub-Saharan Africa with demonstrated sensitivity and specificity of 100% compared to the Abbott M2000 HCV Real time assay as a reference. The test also demonstrated efficiency of 95.4% (result achieved at first attempt).\n \ngenedrive plc has signed a distribution agreement with Sysmex Europe GmbH, a su...